Literature DB >> 11224046

Effects of tianeptine on spontaneous alternation, simple and concurrent spatial discrimination learning and on alcohol-induced alternation deficits in mice.

R. Jaffard1, E. Mocaer, J-C. Poignant, J. Micheau, A. Marighetto, M. Meunier, D. Béracochéa.   

Abstract

The effects of systemic administration of tianeptine, a new psychotropic agent with antidepressant properties, were investigated on spontaneous alternation behavior, and on simple and concurrent spatial discrimination, in normal mice of the BALB/c strain. Tianeptine increased rates of spontaneous T-maze alternation, facilitated retention of a T-maze left-right discrimination, and speeded up acquisition of concurrent discrimination in a radial maze. These effects were consistent across successive experiments with a dose of 10mg/kg; lower doses (2.5 and 5.0mg/kg) had less or no effect depending on the task. These results, together with theoretical considerations, led us to investigate the effect of tianeptine on the sequential-specific alternation deficit induced by long-term ethanol administration in the same strain of mice. Results showed that, at the dose of 10mg/kg, the drug completely alleviated the alcohol-induced deficit. Unlike tianeptine, fluoxetine impaired discrimination performance in the radial maze. These data are discussed in light of the effects of tianeptine on serotonergic transmission and of the role of serotonin and acetylcholine in learning and memory processes.

Entities:  

Year:  1991        PMID: 11224046

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  16 in total

Review 1.  Collapsin response mediator protein-2: an emerging pathologic feature and therapeutic target for neurodisease indications.

Authors:  Kenneth Hensley; Kalina Venkova; Alexandar Christov; William Gunning; Joshua Park
Journal:  Mol Neurobiol       Date:  2011-01-28       Impact factor: 5.590

2.  Effects of acute and chronic antidepressant treatments on memory performance: a comparison between paroxetine and imipramine.

Authors:  Laurent Naudon; Maïté Hotte; Thérèse M Jay
Journal:  Psychopharmacology (Berl)       Date:  2007-01-12       Impact factor: 4.530

Review 3.  Tianeptine: a review of its use in depressive disorders.

Authors:  A J Wagstaff; D Ormrod; C M Spencer
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

4.  Comparative pharmacodynamic studies with the novel serotonin uptake-enhancing tianeptine and -inhibiting fluvoxamine utilizing EEG mapping and psychometry.

Authors:  B Saletu; J Grünberger; P Anderer; L Linzmayer; G Zyhlarz
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

5.  Antidepressants are a rational complementary therapy for the treatment of Alzheimer's disease.

Authors:  Marwa Aboukhatwa; Laura Dosanjh; Yuan Luo
Journal:  Mol Neurodegener       Date:  2010-03-12       Impact factor: 14.195

Review 6.  Neurobiological and clinical effects of the antidepressant tianeptine.

Authors:  Siegfried Kasper; Bruce S McEwen
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

7.  Comparative study of the effects of tianeptine and other antidepressants on the activity of medial septal neurons in rats anesthetized with urethane.

Authors:  M H Bassant; B H Lee; F Jazat; Y Lamour
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-11       Impact factor: 3.000

Review 8.  Tianeptine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depression and coexisting anxiety and depression.

Authors:  M I Wilde; P Benfield
Journal:  Drugs       Date:  1995-03       Impact factor: 9.546

9.  Tianeptine: an antidepressant with memory-protective properties.

Authors:  Phillip R Zoladz; Collin R Park; Carmen Muñoz; Monika Fleshner; David M Diamond
Journal:  Curr Neuropharmacol       Date:  2008-12       Impact factor: 7.363

Review 10.  The neurobiological properties of tianeptine (Stablon): from monoamine hypothesis to glutamatergic modulation.

Authors:  B S McEwen; S Chattarji; D M Diamond; T M Jay; L P Reagan; P Svenningsson; E Fuchs
Journal:  Mol Psychiatry       Date:  2009-08-25       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.